Publications by authors named "E Moreno-Osset"
Article Synopsis
- Anti-TNF drugs, specifically adalimumab (ADA), have significantly improved treatment outcomes for Crohn's disease (CD), particularly in achieving endoscopic and possibly transmural healing as assessed by ultrasound.
- A study of 92 CD patients on ADA indicated that higher serum concentrations of the drug during the first year of treatment were associated with better sonographic signs of transmural healing.
- However, this correlation did not persist after one year, suggesting that long-term management may require different approaches or monitoring strategies.
Aim: endoscopy identifies inflammatory activity, however, it is an unpleasant test and is not always accessible. The aim of the study was to compare the usefulness of quantitative fecal immunochemical test (FIT) versus fecal calprotectin (FC) to determine endoscopic activity in patients with inflammatory bowel disease (IBD).
Methods: cross-sectional prospective observational study.
Background/aims: Tight control of inflammation and adjustment of treatment if activity persists is the current strategy for the management of Crohn's disease (CD). The usefulness of fecal calprotectin (FC) in isolated involvement of the small intestine in CD is controversial. To assess the usefulness of FC to determine the inflammatory activity detected by intestinal ultrasonography (IUS) in ileal CD.
View Article and Find Full Text PDFObjective: to assess the usefulness of medical treatment to achieve closure of internal fistulas detected on abdominal ultrasound in a series of patients with fistulizing Crohn's disease.
Material And Methods: a retrospective analysis was performed of the medical records of patients with Crohn's disease with a fistula detected on abdominal ultrasound from 2010 to 2018. The study included patients who received medical treatment after the diagnosis of this complication and underwent ultrasonographic monitoring of the therapeutic response.
Aim: To assess the clinical benefits of transmural healing (TH) shown on intestinal ultrasound (IUS) after treatment with tumor necrosis factor-alpha antibodies (anti-TNF) in patients with Crohn's disease.
Materials And Methods: This prospective study included consecutively 36 patients who underwent IUS in the week prior to start anti-TNF treatment, at 12 weeks, and 1 year after starting treatment. The clinical response to treatment was assessed using the Crohn's disease activity index and C-reactive protein (CRP) values.